p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes

Laura Patrussi, Nagaja Capitani, Francesca Cattaneo, Noemi Manganaro, Alessandra Gamberucci, Federica Frezzato, Veronica Martini, Andrea Visentin, Pier Giuseppe Pelicci, Mario M. D’Elios, Livio Trentin, Gianpietro Semenzato, Cosima T. Baldari

Research output: Contribution to journalArticle

Abstract

Neoplastic cell traffic abnormalities are central to the pathogenesis of chronic lymphocytic leukemia (CLL). Enhanced CXC chemokine receptor-4 (CXCR4) and chemokine receptor-7 (CCR7) recycling contributes to the elevated surface levels of these receptors on CLL cells. Here we have addressed the role of p66Shc, a member of the Shc family of protein adaptors the expression of which is defective in CLL cells, in CXCR4/CCR7 recycling. p66Shc reconstitution in CLL cells reduced CXCR4/CCR7 recycling, lowering their surface levels and attenuating B-cell chemotaxis, due to their accumulation in Rab5+ endosomes as serine-phosphoproteins bound to β-arrestin. This results from the ability of p66Shc to inhibit Ca2+ and PP2B-dependent CXCR4/CCR7 dephosphorylation and β-arrestin release. We also show that ibrutinib, a Btk inhibitor that promotes leukemic cell mobilization from lymphoid organs, reverses the CXCR4/CCR7 recycling abnormalities in CLL cells by increasing p66Shc expression. These results, identifying p66Shc as a regulator of CXCR4/CCR7 recycling in B cells, underscore the relevance of its deficiency to CLL pathogenesis and provide new clues to the mechanisms underlying the therapeutic effects of ibrutinib.

Original languageEnglish
Pages (from-to)1-17
Number of pages17
JournalOncogene
DOIs
Publication statusAccepted/In press - Jan 12 2018

Fingerprint

CXCR4 Receptors
Arrestin
Chemokine Receptors
Endosomes
Recycling
B-Cell Chronic Lymphocytic Leukemia
Shc Signaling Adaptor Proteins
B-Lymphocytes
Aptitude
Phosphoproteins
Therapeutic Uses
Chemotaxis
Serine

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes. / Patrussi, Laura; Capitani, Nagaja; Cattaneo, Francesca; Manganaro, Noemi; Gamberucci, Alessandra; Frezzato, Federica; Martini, Veronica; Visentin, Andrea; Pelicci, Pier Giuseppe; D’Elios, Mario M.; Trentin, Livio; Semenzato, Gianpietro; Baldari, Cosima T.

In: Oncogene, 12.01.2018, p. 1-17.

Research output: Contribution to journalArticle

Patrussi, L, Capitani, N, Cattaneo, F, Manganaro, N, Gamberucci, A, Frezzato, F, Martini, V, Visentin, A, Pelicci, PG, D’Elios, MM, Trentin, L, Semenzato, G & Baldari, CT 2018, 'p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes', Oncogene, pp. 1-17. https://doi.org/10.1038/s41388-017-0066-2
Patrussi, Laura ; Capitani, Nagaja ; Cattaneo, Francesca ; Manganaro, Noemi ; Gamberucci, Alessandra ; Frezzato, Federica ; Martini, Veronica ; Visentin, Andrea ; Pelicci, Pier Giuseppe ; D’Elios, Mario M. ; Trentin, Livio ; Semenzato, Gianpietro ; Baldari, Cosima T. / p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes. In: Oncogene. 2018 ; pp. 1-17.
@article{a5c48c6d870f437185da2388a4726969,
title = "p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes",
abstract = "Neoplastic cell traffic abnormalities are central to the pathogenesis of chronic lymphocytic leukemia (CLL). Enhanced CXC chemokine receptor-4 (CXCR4) and chemokine receptor-7 (CCR7) recycling contributes to the elevated surface levels of these receptors on CLL cells. Here we have addressed the role of p66Shc, a member of the Shc family of protein adaptors the expression of which is defective in CLL cells, in CXCR4/CCR7 recycling. p66Shc reconstitution in CLL cells reduced CXCR4/CCR7 recycling, lowering their surface levels and attenuating B-cell chemotaxis, due to their accumulation in Rab5+ endosomes as serine-phosphoproteins bound to β-arrestin. This results from the ability of p66Shc to inhibit Ca2+ and PP2B-dependent CXCR4/CCR7 dephosphorylation and β-arrestin release. We also show that ibrutinib, a Btk inhibitor that promotes leukemic cell mobilization from lymphoid organs, reverses the CXCR4/CCR7 recycling abnormalities in CLL cells by increasing p66Shc expression. These results, identifying p66Shc as a regulator of CXCR4/CCR7 recycling in B cells, underscore the relevance of its deficiency to CLL pathogenesis and provide new clues to the mechanisms underlying the therapeutic effects of ibrutinib.",
author = "Laura Patrussi and Nagaja Capitani and Francesca Cattaneo and Noemi Manganaro and Alessandra Gamberucci and Federica Frezzato and Veronica Martini and Andrea Visentin and Pelicci, {Pier Giuseppe} and D’Elios, {Mario M.} and Livio Trentin and Gianpietro Semenzato and Baldari, {Cosima T.}",
year = "2018",
month = "1",
day = "12",
doi = "10.1038/s41388-017-0066-2",
language = "English",
pages = "1--17",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes

AU - Patrussi, Laura

AU - Capitani, Nagaja

AU - Cattaneo, Francesca

AU - Manganaro, Noemi

AU - Gamberucci, Alessandra

AU - Frezzato, Federica

AU - Martini, Veronica

AU - Visentin, Andrea

AU - Pelicci, Pier Giuseppe

AU - D’Elios, Mario M.

AU - Trentin, Livio

AU - Semenzato, Gianpietro

AU - Baldari, Cosima T.

PY - 2018/1/12

Y1 - 2018/1/12

N2 - Neoplastic cell traffic abnormalities are central to the pathogenesis of chronic lymphocytic leukemia (CLL). Enhanced CXC chemokine receptor-4 (CXCR4) and chemokine receptor-7 (CCR7) recycling contributes to the elevated surface levels of these receptors on CLL cells. Here we have addressed the role of p66Shc, a member of the Shc family of protein adaptors the expression of which is defective in CLL cells, in CXCR4/CCR7 recycling. p66Shc reconstitution in CLL cells reduced CXCR4/CCR7 recycling, lowering their surface levels and attenuating B-cell chemotaxis, due to their accumulation in Rab5+ endosomes as serine-phosphoproteins bound to β-arrestin. This results from the ability of p66Shc to inhibit Ca2+ and PP2B-dependent CXCR4/CCR7 dephosphorylation and β-arrestin release. We also show that ibrutinib, a Btk inhibitor that promotes leukemic cell mobilization from lymphoid organs, reverses the CXCR4/CCR7 recycling abnormalities in CLL cells by increasing p66Shc expression. These results, identifying p66Shc as a regulator of CXCR4/CCR7 recycling in B cells, underscore the relevance of its deficiency to CLL pathogenesis and provide new clues to the mechanisms underlying the therapeutic effects of ibrutinib.

AB - Neoplastic cell traffic abnormalities are central to the pathogenesis of chronic lymphocytic leukemia (CLL). Enhanced CXC chemokine receptor-4 (CXCR4) and chemokine receptor-7 (CCR7) recycling contributes to the elevated surface levels of these receptors on CLL cells. Here we have addressed the role of p66Shc, a member of the Shc family of protein adaptors the expression of which is defective in CLL cells, in CXCR4/CCR7 recycling. p66Shc reconstitution in CLL cells reduced CXCR4/CCR7 recycling, lowering their surface levels and attenuating B-cell chemotaxis, due to their accumulation in Rab5+ endosomes as serine-phosphoproteins bound to β-arrestin. This results from the ability of p66Shc to inhibit Ca2+ and PP2B-dependent CXCR4/CCR7 dephosphorylation and β-arrestin release. We also show that ibrutinib, a Btk inhibitor that promotes leukemic cell mobilization from lymphoid organs, reverses the CXCR4/CCR7 recycling abnormalities in CLL cells by increasing p66Shc expression. These results, identifying p66Shc as a regulator of CXCR4/CCR7 recycling in B cells, underscore the relevance of its deficiency to CLL pathogenesis and provide new clues to the mechanisms underlying the therapeutic effects of ibrutinib.

UR - http://www.scopus.com/inward/record.url?scp=85040342344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040342344&partnerID=8YFLogxK

U2 - 10.1038/s41388-017-0066-2

DO - 10.1038/s41388-017-0066-2

M3 - Article

AN - SCOPUS:85040342344

SP - 1

EP - 17

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -